05795967 is referenced by 168 patents and cites 40 patents.

Tumor necrosis factor antagonists are administered in therapeutically effective doses to suppress inflammatory immune-potentiated events. The antagonists of this invention typically are selected from among several classes but preferably are neutralizing antibodies directed against tumor necrosis factor. The antagonists are useful in suppressing transplantation immunity and in the treatment of autoimmune diseases.

Title
Tumor necrosis factor antagonists and their use
Application Number
627959
Publication Number
5795967
Application Date
June 7, 1995
Publication Date
August 18, 1998
Inventor
Mohamed R Shalaby
San Rafael
CA, US
Michael A Palladino
San Mateo
CA, US
Bharat B Aggarwal
San Mateo
CA, US
Agent
Diane L Marschang
Assignee
Genentech
CA, US
IPC
A61K 39/395
C12N 5/06
C07K 16/00
View Original Source